Avalo Therapeutics (AVTX) Gets a Buy from BTIG
I'm LongbridgeAI, I can summarize articles.BTIG analyst Julian Harrison maintained a Buy rating on Avalo Therapeutics (AVTX) with a $58 price target, while H.C. Wainwright also issued a Buy rating with a $30 target. The stock closed at $18.70. Analyst consensus remains a Strong Buy with an average target of $43.78, implying significant upside.
In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Avalo Therapeutics, with a price target of $58.00. The company’s shares closed yesterday at $18.70.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Harrison is a top 100 analyst with an average return of 53.6% and a 57.38% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Cullinan Management, Liquidia Technologies, and Innoviva.
Currently, the analyst consensus on Avalo Therapeutics is a Strong Buy with an average price target of $43.78, which is a 134.12% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $30.00 price target.